Expression of interleukin-1 receptor antagonist in human pituitary adenomas in vitro.

J Clin Endocrinol Metab

Max-Planck-Institute of Psychiatry, Clinical Institute, Munich, Germany.

Published: December 1994

The production of cytokines and their receptors in the pituitary gland as well as receptor-mediated cytokine effects on pituitary function have been demonstrated. We have investigated whether the naturally occurring interleukin-1 receptor antagonist (IL-1ra), which has been shown to block IL-1 biological actions during inflammatory processes, could be expressed in human pituitary adenomas (n = 16) cultured in vitro. By polymerase chain reaction of reverse-transcribed RNA we detected IL-1ra messenger RNA in cultures of all types of pituitary adenomas under basal conditions as well as after stimulation of the cells with endotoxin or phorbol myristate acetate. The amplified complementary DNA fragment was identical to the fragment observed when RNA from purified human monocytes was subjected to reverse transcription polymerase chain reaction. In addition, we provide evidence that the IL-1ra messenger RNA detected in human pituitary adenomas corresponds to the intracellular IL-1ra variant. By using specific primers for the monocyte/macrophage marker CD14 as a control, we could exclude a contamination by monocytes or macrophages in the cell cultures of pituitary adenomas as a source of IL-1ra expression. Immunofluorescence studies showed the presence of cellular IL-1ra protein in the pituitary adenoma cultures and the colocalization with hormone-producing cells in GH- and ACTH-secreting adenomas. Production of IL-1ra within the anterior pituitary may act as a protective mechanism, modulating the sensitivity of pituitary cells to circulating or intrinsically produced IL-1 during inflammatory or tumoral processes.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jcem.79.6.7989495DOI Listing

Publication Analysis

Top Keywords

pituitary adenomas
20
human pituitary
12
pituitary
10
interleukin-1 receptor
8
receptor antagonist
8
polymerase chain
8
chain reaction
8
rna detected
8
il-1ra messenger
8
messenger rna
8

Similar Publications

Microprolactinoma Growth During Pregnancy With Pituitary Tumor Apoplexy: Case Report and Review of the Literature.

Case Rep Endocrinol

January 2025

Unidad Académica de Endocrinología y Metabolismo, Hospital de Clínicas "Dr. Manuel Quíntela", Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.

Prolactinomas are the most prevalent subtype of pituitary adenomas and represent one of the leading etiological factors responsible for amenorrhea and infertility in women. The primary therapeutic approach entails the use of dopamine agonists, which effectively restore fertility. In cases of microprolactinomas, the likelihood of experiencing a symptomatic enlargement of the tumor during pregnancy is exceptionally low, estimated at a mere 2.

View Article and Find Full Text PDF

Introduction: The role of stereotactic radiosurgery (SRS) in pituitary adenomas (PAs) is evolving especially considering its safety. Existing literature is hampered by limited sample sizes and short-term follow-ups, impeding its preeminence in the clinical and radiological outcomes. We propose a comprehensive, single-centred study to evaluate the outcomes following CyberKnife stereotactic radiosurgery (CK SRS) for PAs in a larger patient population, incorporating meticulous clinical and radiological follow-up.

View Article and Find Full Text PDF

Surgical treatment of complex pituitary adenomas (PAs) presents a significant challenge. Here in, we compared the surgical outcomes between patients undergoing endoscope-assisted transcranial surgery and microscopic regimens to assess the safety and efficacy of endoscope-assisted transcranial surgery in treating complex PA. This retrospective case-control study was conducted at the First Affiliated Hospital of Soochow University, China.

View Article and Find Full Text PDF

Pituitary neuroendocrine tumors remain one of the most common intracranial tumors. While radiomic research related to pituitary tumors is progressing, public data sets for external validation remain scarce. We introduce an open dataset comprising high-resolution T1 contrast-enhanced MR scans of 136 patients with pituitary tumors, annotated for tumor segmentation and accompanied by clinical, radiological and pathological metadata.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!